NHF’s Medical and Scientific Advisory Council (MASAC) recently issued six new documents, all of which were adopted by NHF’s Board of Directors on April 27, 2022.
MASAC Document #267 contains a series of detailed recommendations relevant to prophylaxis for individuals with severe hemophilia A and B, including those with inhibitors.
MASAC Document #268 encompasses comprehensive recommendations on the use of emicizumab for individuals with hemophilia A, including guidance for healthcare providers encountering a variety of clinical scenarios including surgery and acute bleeding events.
MASAC Document #269 describes the fundamental components of integrated care at hemophilia treatment centers for patients with inherited bleeding disorders
View and download Standards and Criteria for the Care of Persons with Congenital Bleeding Disorders.
MASAC Document #270 provides important screening guidance for those patients with viral hepatitis who are at a higher risk for liver cancer.
MASAC Document #271 includes several practical recommendations to ensure that home use of bypassing agents is a viable option for patients and their families.
MASAC Document #272 is the latest version of the council’s enduring and most broad-based treatment document, which includes descriptions of, and recommendations for, the use of all therapies currently approved by the U.S. Food and Drug Administration to treat inheritable bleeding disorders.
View the complete list of current MASAC documents.
